Christopher Pierce
Nessuna posizione attualmente
Profilo
Christopher Pierce worked as Senior Director-Hematologic Malignancies Portfolio at Pfizer Inc. from 2016 to 2017.
He then worked as Vice President & Head-Commercial at Loxo Oncology, Inc. from 2017 to 2019.
In 2019, he worked as Principal at Scout Advisers LLC.
In 2020, he worked as Chief Business Operations & Executive VP at Prelude Therapeutics, Inc. Mr. Pierce holds an MBA from Harvard Business School and an undergraduate degree from Harvard College.
Precedenti posizioni note di Christopher Pierce
| Società | Posizione | Fine |
|---|---|---|
| PRELUDE THERAPEUTICS INCORPORATED | Corporate Officer/Principal | 30/09/2021 |
| Scout Advisers LLC | Corporate Officer/Principal | 01/07/2020 |
| LOXO ONCOLOGY INC | Corporate Officer/Principal | 01/05/2019 |
| PFIZER, INC. | Corporate Officer/Principal | 01/03/2017 |
Formazione di Christopher Pierce
| Harvard Business School | Masters Business Admin |
| Harvard College | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| PRELUDE THERAPEUTICS INCORPORATED | Health Technology |
| Aziende private | 2 |
|---|---|
Loxo Oncology, Inc.
 Loxo Oncology, Inc. Pharmaceuticals: MajorHealth Technology Loxo Oncology, Inc. is a biopharmaceutical company, which engages in the development of small molecule therapeutics for the treatment of cancer. It focuses on genetic alterations, targeted therapies, and genetic testing. The company was founded by Joshua H. Bilenker in May 2013 and is headquartered in Stamford, CT. | Health Technology |
| Scout Advisers LLC |
- Borsa valori
- Insiders
- Christopher Pierce
